These 2 Stocks Are Trading at a Once-in-a-Lifetime Price
The coronavirus has been bad news for U.S. stock prices. The Dow Jones Industrial Average has given back most of its gains during the Donald Trump presidency, and scores of blue-chip equities are now trading at multiyear lows as a result. Despite this historic marketwide drop in stock prices, however, most equities still aren’t worth buying right now. The unfortunate truth is that the pandemic is probably several weeks away from hitting a peak in the United States, making it virtually impossible to open up the broader economy. So with little to no economic activity on the near-term horizon, stock prices are bound to print lower lows as this public health crisis deepens during the month of April.
But there are a few bright spots in this dour market. Companies that produce products essential to daily life, such as medical devices and pharmaceuticals, should eventually separate themselves from the pack. Keeping with this theme, the diabetes medical device specialist DexCom (NASDAQ:DXCM) and the pharmaceutical titan Pfizer (NYSE:PFE) are both trading at once-in-a-lifetime prices right now. Here’s why investors may want to add these two top healthcare stocks to their portfolios soon.
DexCom: a V-shaped rebound is already taking shape
DexCom is a medical device specialist focused on battling another global pandemic: diabetes. There are an estimated 463 million adults living with diabetes at the moment. What’s more, the adult diabetic population is forecast to grow at an alarming rate during the current decade, thanks to the global rise in obesity and sedentary lifestyles.
DexCom, for its part, is pitching in to help in the fight against diabetes with its game-changing G6 continuous glucose monitoring (CGM) system. By allowing patients to carefully monitor their glucose levels, this device should ultimately have a significant impact on the prevalence of diabetes-related complications such as nerve degeneration, cardiovascular disease, kidney failure, and blindness.
And so far, the… Continue reading at The Motley Fool